ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 301c
Tweet
Share
E-mailGet Alerts ATRA Hot Sheet
Join SI Premium – FREE
ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($3.10), $3.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $28.64 million versus the consensus estimate of $37.09 million.
For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
- Nakamoto closes healthcare clinics, completes shift to Bitcoin
- Qnity launches advanced packaging hub for AI and chip markets
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
